Nocimed is pleased to announce an upcoming segment on the television show “Inside Business” hosted by Fred Thompson featuring Nocimed’s investigational Nociscan Virtual Discogram MR spectroscopy diagnostic technology and product in clinical development. This segment is scheduled to broadcast nationally on the Discovery Channel, via most major cable and satellite providers across the United States, on Thursday, May 10 between 7-7:30am Eastern and Pacific, 6-6:30am Central, and 5-5:30am Mountain times; and at two additional dates and times still to be scheduled. This segment will also be broadcast via CNN Headline News in certain specific regional markets and time slots, initially to include: Minneapolis-St. Paul (Charter cable network) on Sunday, May 6 at 6:54am, 8:54am, and 5:24pm; Seattle-Tacoma (Comcast cable network) on Friday, May 11 at 12:24pm and 1:24pm and Sunday, May 12 at 9:24am; and New York at four dates and times yet to be scheduled. A streaming video link also showing this feature segment, and updates regarding its future scheduled broadcasts, are expected to be provided for a limited time at http://www.nocimed.com/mediacenter_newsroom.html.
About Nociscan Virtual Discogram
The Nociscan Virtual Discogram is an investigational new software-based application of magnetic resonance spectroscopy (MRS) – an available mode of using most high field MR systems for non-invasively measuring tissue chemistry adjunctive to “MRI” for imaging tissue structures. This is being developed for potential future use with standard commercially available MR hardware to supplement standard MRI exams of the lumbar spine in order to non-invasively measure and assess tissue chemistry of intervertebral discs. This is being evaluated in clinical studies to potentially aid in the assessment of degenerative disc disease and discogenic low back pain. Back pain is estimated to represent the leading reported cause and cost of worker’s compensation and disability claims, the second leading reported cause for doctor visits in middle-aged patients, and the leading category of all MRI diagnostic procedures. The Nociscan technology and procedure involves a proprietary protocol for acquiring MRS data from discs, and securely uploading the data to a Nociscan cloud server where a proprietary software-based Sigpro post-processor automatically processes the data to generate a Nocigram report. These results provide information related to the chemical environment in the discs examined, and may be securely communicated or accessed electronically. The investigational Nociscan Virtual Discogram was awarded “#1 Overall Best New Technology in Spine for 2011” by Orthopedics This Week, a leading magazine in spine and orthopedics.
CAUTION: Investigational device. Limited by Federal law to investigational use.
Nocimed, LLC is a privately held Delaware limited liability company with its principal operations based in Redwood City, CA. Nocimed was founded in 2008 to develop technologies for the diagnosis of tissue degeneration and pain, and with particular focus on diagnosing degenerative musculoskeletal (MSK) pain. The company’s first and primary investigational product – the Nociscan Virtual Discogram – is a new software-based application of magnetic resonance spectroscopy (MRS). A suite of individual MRS-related software utilities are also being developed to support the Nociscan application. These are also being evaluated as potential products in the future under a broader mission to develop and provide value-added diagnostic applications to address areas of significant unmet clinical needs – especially in the areas of MSK, pain, and software as a service (SaaS). The company’s current research is supported in part by active collaborations with multiple MR system manufacturers, and funded by various grants and qualified private investments from accredited investors. The company expects such continued research support may be augmented with increasing exposure of the on-going research activities and potential future directions.
Nocimed™, Nociscan™ Virtual Discogram™, Sigpro™, and Nocigram™ are proprietary trademarks of Nocimed, LLC (all rights reserved). Parties interested in contacting the company with specific inquiries, such as to learn more about or potentially support or collaborate in our research, may do so by calling Chris Wakeman (650)241-1727 or via email to email@example.com. Further information may be found generally at http://www.nocimed.com.